Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul 20:2022:6836942.
doi: 10.1155/2022/6836942. eCollection 2022.

Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis

Xinyi Guo  1 , Changxing Liu  1 , Yahui Huang  2
Affiliations
Meta-Analysis

Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis

Xinyi Guo et al. Comput Math Methods Med. .

Abstract

Objective: To examine the clinical efficacy and safety of Vitamin D in the treatment of ulcerative colitis in a systematic manner.

Methods: RCT studies on Vitamin D in the treatment of ulcerative colitis were searched from CNKI, Wanfang Data, PubMed, Cochrane Library, and Web of Science databases. RevMan 5.4 software was used for analysis.

Results: 10 articles were included, including 1077 patients. Meta-analysis results showed that when clinical efficacy was used as the outcome index, the clinical efficacy of the oral vitamin group was higher than that of the conventional treatment group (OR = 4.07, 95% CI 2.64-6.27), and the difference was statistically significant (Z = 6.38, P < 0.00001). When the Mayo risk score was used as the outcome index, the difference was statistically significant, indicating that oral Vitamin D significantly reduced the Mayo risk score (MD: -0.41, CI = (-0.47, -0.34), Z = 13.09, P < 0.00001). Using the intestinal mucosal barrier as the outcome index, the results showed that (1) the MDA group (MD = -0.75, 95% CI (-0.96~-0.53), P < 0.00001), (2) the DAO group (MD = -1.17, 95% CI (-1.39-0.95), P < 0.00001), and the Vitamin D group could effectively improve intestinal mucosal barrier function after sensitivity analysis (MD = -1.00, 95% CI (-1.08-0.92), P < 0.00001). When inflammatory factors were used as outcome indicators, IL-6, TNF-α, and CRP groups had statistical significance (MD = -4.50, 95% CI (-5.13-3.87), P < 0.00001); MD = -7.27, 95% CI (18.96-5.58), P < 0.00001; and MD = -1.49, 95% CI (-1.76~-1.23), P < 0.00001, respectively). When the incidence of adverse reactions was used as the outcome indicator (OR = 0.73, 95% CI (0.34-1.32), P = 0.23), there was no significant difference between the two groups.

Conclusion: Vitamin D combined with mesalazine is effective in the treatment of ulcerative colitis, by improving the Mayo score and intestinal barrier function, and reducing inflammatory factors, with no significant safety difference. However, due to the quality of the included researches, more RCT researches needed to provide sufficient evidence to support clinical application. This study is registered with INPLASY 202250044.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Specific process of literature screening.
Figure 2
Figure 2
Risk of bias in the included literature for vitamin D treatment of UC.
Figure 3
Figure 3
Forest map of clinical efficacy comparison.
Figure 4
Figure 4
Forest map of Mayo score comparison.
Figure 5
Figure 5
Forest map comparing inflammatory factors.
Figure 6
Figure 6
Forest map of intestinal barrier function comparison.
Figure 7
Figure 7
Sensitivity analysis of intestinal barrier function.
Figure 8
Figure 8
Forest plot comparing the incidence of adverse reactions.
Figure 9
Figure 9
Funnel plot.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ordás I., Eckmann L., Talamini M., Baumgart D. C., Sandborn W. J. Ulcerative colitis. The Lancet . 2012;380(9853):1606–1619. doi: 10.1016/S0140-6736(12)60150-0. - DOI - PubMed
    1. Liang X., Yin F., Zhang X. Consensus opinion on diagnosis and treatment of inflammatory bowel disease (2018, Beijing) part interpretation of ulcerative colitis. Clinical Meta-Analysis . 2018;33(11):987–990.
    1. Adams S. M., Bornemann P. H. Ulcerative colitis. American Family Physician . 2013;87(10):699–705. - PubMed
    1. Yagisawa K., Kobayashi T., Ozaki R., et al. Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. Intestinal Research . 2019;17(1):87–93. doi: 10.5217/ir.2018.00078. - DOI - PMC - PubMed
    1. Cantorna M. T. Vitamin D, multiple sclerosis and inflammatory bowel disease. Archives of Biochemistry and Biophysics . 2012;523(1):103–106. doi: 10.1016/j.abb.2011.11.001. - DOI - PMC - PubMed

Publication types